FibroGen (FGEN) sees Significant Insider Selling Continuing

Wednesday, November 01, 2017 10:15 PM ET

FibroGen (FGEN) sees Significant Insider Selling Continuing

A filing with the SEC today revealed a significant insider sale of FibroGen shares as — Thomas B Neff, Director and Officer — disposed of 38,636 shares in the company having a market value of approximately $2,168,449. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 198,746 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 237,382 shares and have averaged 39,564 shares per transaction over this time period.

The number of insider buy/sell trades at FibroGen is above that of the 184 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 209 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by FibroGen insiders is lower than its peers. Within the peer group there were 22,586,199 shares purchased and 51,313,333 shares sold with company insiders selling 137,450 shares on average over this time period.

The data sourced in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.